| Formulary Chapter 6: Endocrine system - Full Chapter
|
| 06.01.02.03 |
Other antidiabetic drugs |
|
|
| 06.01.02.03 |
DPP-4 inhibitors |
|
|
| 06.01.02.03 |
Alpha glucosidase inhibitors |
|
|
| 06.01.02.03 |
GLP-1 mimetics |
|
|
| 06.01.02.03 |
DPP4 inhibitors (gliptins) |
|
|
| 06.01.02.03 |
SGLT2 inhibitors |
|
|
| 06.01.02.03 |
GLP1 agonists |
|
|
Liraglutide (Saxenda®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
• Injection
• For weight loss/ obesity
• Use according to NICE guidance
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes
|
Semaglutide (Wegovy ®)
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on Prescribing; manufacturer advises to record the brand name and batch number after each administration.
The use of semaglutide for this indication is restricted to prescribing by commissioned clinics in secondary care by a consultant led specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
|
| 06.01.02.03 |
SGL2 inhibitors |
|
|
| 06.01.02.03 |
Thiazolidinediones |
|
|
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
All Settings
Suitable for initiation, ongoing prescribing, and discontinuation in both primary and secondary care settings. They are generally familiar, frequently used therapies that can be started within their licensed indications without specialist oversight. |
|
Specialist only
Designated for initiation, ongoing prescribing, monitoring, exclusively by a specialists either in a hospital or as part of a specialist service (to note this could be in a non-hospital setting). Primary care should neither start nor continue these treatments except as part of a specialist service. A specialist could be either a medical or non-medical prescriber. |
|
Specialist advice
Prescribers in primary care should seek advice and a recommendation from a specialists prior to initiating a medicine. Once agreed with a specialist, medicines can be initiated, prescribed and monitored in primary care without a formal shared-care agreement. |
|
Specialist initiation
Medicines in this category require a specialist to start therapy, titrate dosage, and assess initial efficacy or tolerability. Once stabilised, prescribing responsibility may transfer to primary care without the need for a formal shared-care agreement. |
|
Shared care agreement
Prescribing responsibility can be shared across health settings and between specialists and GPs only when formal shared care arrangement has been made. For example, there may be extensive and complex monitoring requirements or significant safety concerns (note would need a national policy on this to define the criteria for requiring a formal SCA), this will be produced once nationally. |
|
Do not prescribe
Not approved for routine prescribing in primary or secondary care. For example, because they are agents classified in the BNF as “not NHS” or “Drugs of Low Clinical Value”, or they are products on NICE’s “do not do” list or NHS England’s “should not routinely prescribe” list. |
|
Self Care
Not for routine prescribed in primary or secondary care unless as part of care for a long term condition. Instead, patients should be encouraged to self care with support from community pharmacy. |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
|
